sunesis pharmaceuticals inc (SNSS) Details

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including a Phase III clinical trial, known as the VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II/III trial known as the LI-1 trial in patients older than 60 years with AML or high-risk myelodysplastic syndrome. In addition, the company has completed the Phase II portion of a Phase Ib/II trial of Vosaroxin in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and Phase II trial in previously untreated patients with 60 years of age or older with AML or REVEAL-1 trial, which explored three dosing schedules of vosaroxin. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.

sunesis pharmaceuticals inc (SNSS) Top Compensated Officers